Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at Benchmark

Benchmark reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note released on Tuesday morning, Benzinga reports. Benchmark currently has a $8.00 target price on the biopharmaceutical company’s stock.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $7.54 on Tuesday. The company has a market capitalization of $395.10 million, a price-to-earnings ratio of -0.68 and a beta of 1.62. The company has a quick ratio of 0.55, a current ratio of 1.08 and a debt-to-equity ratio of 0.67. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $8.29. The stock has a fifty day simple moving average of $5.42 and a 200 day simple moving average of $3.34.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($3.65) by $4.24. The company had revenue of $300.40 million during the quarter. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. During the same period in the previous year, the company posted ($3.17) EPS. Sell-side analysts expect that Emergent BioSolutions will post -1.98 EPS for the current year.

Insider Activity

In related news, Director Kathryn C. Zoon sold 10,000 shares of Emergent BioSolutions stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now owns 54,482 shares of the company’s stock, valued at $332,885.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 12,919 shares of company stock valued at $75,831. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Emergent BioSolutions

A number of large investors have recently bought and sold shares of the business. Laurion Capital Management LP bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at about $37,000. Avidian Wealth Solutions LLC acquired a new stake in shares of Emergent BioSolutions during the 1st quarter worth approximately $33,000. Tidal Investments LLC bought a new stake in shares of Emergent BioSolutions in the 1st quarter valued at $34,000. CoreCap Advisors LLC acquired a new position in shares of Emergent BioSolutions during the 4th quarter valued at $33,000. Finally, Tower Research Capital LLC TRC boosted its stake in Emergent BioSolutions by 52.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 6,823 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.